ClinicalTrials.gg
RecruitingNCT07433686Updated Apr 28, 2026

Saskatoon Berry Juice for Muscle Recovery

An interventional study of Dietary Supplement and Placebo in Muscle Damage, sponsored by University of Saskatchewan. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by University of Saskatchewan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This study will evaluated the effect of Saskatoon berry juice on recovery from muscle-damaging exercise.

Read the detailed description

Saskatoon berries are high in polyphenols which are are anti-inflammatory and act as anti-oxidants. They therefore have potential to protect muscle from damage induced by intense exercise. Thirty participants will be randomized to receive Sasaktoon berries (375 ml) or placebo every day for 10 days. On the seventh day participants will perform 6 sets of intense biceps curl exercise. Isometric muscle strength, muscle swelling, and muscle soreness will be assessed before exercise, immediately after exercise, and 24, 48, and 72 hours after the exercise session. We hypothesize the group receiving Saskatoon berries will have faster recovery of muscle strength, and reduction in swelling and muscle soreness after the exercise session.

02

Conditions studied

  • Muscle Damage

Keywords

  • muscle damage
  • Saskatoon berries
  • strength
03

In context

Lead sponsor

University of Saskatchewan is the lead sponsor of 243 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • aged 18-35y

Exclusion criteria

Exclusion Criteria:

  • Conditions that might be affects by exercise as determined by the "Get Active Questionnaire"
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo (375 ml)

    Dietary Supplement: Placebo

  • Experimental
    Saskatoon berry juice (375 ml)

    Saskatoon berry juice

    Dietary Supplement: Dietary Supplement

Interventions

  • Dietary supplementDietary Supplement

    Saskatoon berries (375 ml)

  • Dietary supplementPlacebo

    Placebo (375 ml)

06

What researchers measure

Primary outcomes

  1. Change in isometric biceps strength with a dynamometer (Nm)

    Time frame: 72 hours

Secondary outcomes

  1. Change in biceps muscle thickness with ultrasound (cm)

    Time frame: 72 hours

  2. Change in muscle soreness with visual analog scale (score ranges from 0 to 10). No soreness = 0, maximal soreness = 10

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
  • Physical Activity Complex, University of Saskatchewan
    Saskatoon, Saskatchewan S7N 5B2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07433686
Responsible party
Phil Chilibeck (Professor, University of Saskatchewan) — Principal investigator
First posted
Feb 25, 2026
Start date
Feb 26, 2026
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 28, 2026

Study contacts

Philip Chilibeck, PhD
Contact
phil.chilibeck@usask.ca
306-230-3849

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion